Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

Trials to watch: Four ALS drugs to keep an eye on

Yahoo Finance

April 30, 2024

Nanoparticles could help patients with MS, ALS, and Parkinson's

Futurity

April 22, 2024

Nanoparticles Deliver Drugs Directly Across the Blood-Brain Barrier (azonano.com)

AzoNano

April 22, 2024

Multiple Sclerosis Study Shows CNM-Au8 Effective in Remyelination

MedCentral

April 19, 2024

MSU researchers set new standards and show how a new treatment helps patients with MS, ALS, Parkinson’s disease

MSU Today

April 19, 2024

AAN 2024: In MS study, long-term CNM-Au8 shows myelin, nerve cell gains

MS News Today

April 18, 2024

Expected advances in rare disease therapeutics and the role of data in innovation

Clarivate

April 10, 2024

Research identifies ways CNM-Au8 can effectively reach the brain

ALS News Today

March 22, 2024

Gold nanocatalysts cross blood-brain barrier aided by unique protein corona composition

NanoWerk

March 19, 2024

Clene's neurodegenerative disease drug shows promise with new study publication

Biopharma-Reporter

March 18, 2024

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2024 Clene Nanomedicine, Inc. - All rights reserved | PRIVACY POLICY | TERMS OF USE